866-997-4948(US-Canada Toll Free)

Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries

Published By :

GBI Research

Published Date : Oct 2014

Category :

Therapeutic Area

No. of Pages : N/A

GBI Research, the leading business intelligence provider, has released its latest research, ‘Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries’, which provides insights into Major Depressive Disorder (MDD) in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of the pipeline, clinical trial failure rate and deal analysis for MDD. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts. In 2013, the value of the MDD therapeutics market in major developed countries amounted to an estimated $8.7 billion. The market is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 1.1% between 2013 and 2020 to reach $8.1 billion. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period.

Scope

The report analyzes treatment use patterns, market characterization, pipeline analysis and key licensing and co-development deals MDD in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.

The report includes:
  • A brief introduction to MDD, including the disease’s pathophysiology, etiology, diagnosis and treatment algorithms.
  • In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy
  • A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets
  • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type.
  • Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets.
  • Discussion of the drivers and barriers for market growth.
  • In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006.
Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

  • Understand the MDD pipeline and the factors that indicate that it is becoming more innovative. Observe detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be.
  • Follow the trends in MDD clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for MDD therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.
  • Observe the potential growth patterns expected for the MDD market over the forecast period. Identify which countries are expected to contribute the most to this growth and devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the MDD market
  • Accelerate and strengthen your market position by identifying key companies for strategic partnerships.
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Etiology
2.2 Pathophysiology
2.3 Diagnosis
2.4 Classification
2.5 Epidemiology
2.6 Prognosis
2.7 Treatment and Management
2.7.1 Antidepressants

3 Marketed Products
3.1 Therapeutic Landscape
3.1.1 Lexapro/Cipralex (escitalopram) – Lundbeck/Forest Laboratories
3.1.2 Viibryd (vilazodone) – Forest (Actavis)
3.1.3 Cymbalta (duloxetine) – Eli Lilly
3.1.4 Pristiq (desvenlafaxine) – Pfizer
3.1.5 Seroquel XR (quetiapine) – AstraZeneca
3.1.6 Brintellix (vortioxetine) – Takeda and Lundbeck
3.1.7 Abilify (aripiprazole) – Otsuka
3.2 Comparative Efficacy and Safety

4 Major Depressive Disorder Market to 2020 – Pipeline Products
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Patient Enrollment and Clinical Trial Size
4.4.3 Duration
4.5 Promising Drug Candidates in the Pipeline
4.5.1 OPC-34712 (brexpiprazole) – Otsuka and Lundbeck
4.5.2 ALKS-5461 – Alkermes
4.5.3 Amitifadine (EB-1010) – Euthymics Bioscience

5 Market Forecast to 2020
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 North America
5.1.3 Top Five European Countries
5.1.4 Japan
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers

6 Deals and Strategic Consolidations
6.1 Major Licensing Deals
6.1.1 Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets
6.1.2 Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd
6.1.3 AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept
6.1.4 Impax Labs Enters into Licensing Agreement with Wyeth
6.2 Major Co-development Deals
6.2.1 Lundbeck Enters into Co-Development Agreement with Otsuka Pharma
6.2.2 Azaya Lundbeck Enters into Co-Development Agreement with Takeda

7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 Phase I
7.1.4 Phase II
7.1.5 Phase III
7.1.6 Pre-registration
7.1.7 Undisclosed
7.2 Market Forecasts to 2019
7.2.1 Global
7.2.2 US
7.2.3 UK
7.2.4 France
7.2.5 Germany
7.2.6 Italy
7.2.7 Spain
7.2.8 Japan
7.2.9 Canada
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

List of Table

Table 1: Major Depressive Disorder Market, Global, Symptoms and Associated Features, 2008
Table 2: Major Depressive Disorder Market, Global, Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10), 2013
Table 3: Major Depressive Disorder Market, Global, Prevalence (%), 2011
Table 4: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 5: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 6: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 7: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 8: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 9: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Pre-registration), 2013
Table 10: Major Depressive Disorder Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013
Table 11: Major Depressive Disorder Market, Global, Forecast Data, 2013–2020
Table 12: Major Depressive Disorder Market, US, Forecast Data, 2013–2020
Table 13: Major Depressive Disorder Market, UK, Forecast Data, 2013–2020
Table 14: Major Depressive Disorder Market, France, Forecast Data, 2013–2020
Table 15: Major Depressive Disorder Market, Germany, Forecast Data, 2013–2020
Table 16: Major Depressive Disorder Market, Italy, Forecast Data, 2013–2020
Table 17: Major Depressive Disorder Market, Spain, Forecast Data, 2013–2020
Table 18: Major Depressive Disorder Market, Japan, Forecast Data, 2013–2020
Table 19: Major Depressive Disorder Market, Canada, Forecast Data, 2013–2020

List of Chart


Figure 1: Major Depressive Disorder Market, Global, Pathology, 2010
Figure 2: Major Depressive Disorder Market, Global, Stages of Major Depressive Disorder and Respective Treatment Approach, 2010
Figure 3: Major Depressive Disorder Market, Global, Treatment Phases, 2010
Figure 4: Major Depressive Disorder Market, Global, Lexapro (escitalopram) Annual Sales ($bn), 2006–2013
Figure 5: Major Depressive Disorder Market, Global, Viibryd (vilazodone) Annual Sales ($m), 2011–2013
Figure 6: Major Depressive Disorder Market, Global, Cymbalta (duloxetine) Annual Sales ($bn), 2005–2013
Figure 7: Major Depressive Disorder Market, Global, Pristiq (desvenlafaxine) Annual Sales ($m), 2009–2013
Figure 8: Major Depressive Disorder Market, Global, Seroquel XR (quetiapine) Annual Sales ($bn), 2008–2013
Figure 9: Major Depressive Disorder Market, Global, Abilify (aripiprazole) Annual Sales ($bn), 2005–2013
Figure 10: Major Depressive Disorder Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap, 2013
Figure 11: Major Depressive Disorder Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2013
Figure 12: Major Depressive Disorder Market, Global, Pipeline by Molecule Type and Stage of Development, 2013
Figure 13: Major Depressive Disorder Market, Global, Pipeline by Mechanism of Action, 2013
Figure 14: Major Depressive Disorder Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development, 2013
Figure 15: Major Depressive Disorder Market, Global, Clinical Trial Failure Rate (%), 2013
Figure 16: Major Depressive Disorder Market, Global, Clinical Trial Failure Rate by Mechanism of Action (%), 2013
Figure 17: Major Depressive Disorder Market, Global, Clinical Trial Size (Participants), 2013
Figure 18: Major Depressive Disorder Market, Global, Pipeline Clinical Trial Duration (months), 2013
Figure 19: Major Depressive Disorder Market, Global, Treatment Use Patterns and Market Size, 2013–2020
Figure 20: Major Depressive Disorder Market, US and Canada, Treatment Use Patterns (million), 2013–2020
Figure 21: Major Depressive Disorder Market, US and Canada, Annual Cost of Therapy ($), 2013–2020
Figure 22: Major Depressive Disorder Market, US and Canada, Market Size, 2013–2020
Figure 23: Major Depressive Disorder Market, Top Five European Markets, Treatment Use Patterns (million), 2013–2020
Figure 24: Major Depressive Disorder Market, Top Five European Markets, Annual Cost of Therapy ($), 2013–2020
Figure 25: Major Depressive Disorder Market, Top Five European Markets, Market Size ($m), 2013–2020
Figure 26: Major Depressive Disorder Market, Japan, Treatment Use Patterns (million), 2013–2020
Figure 27: Major Depressive Disorder Market, Japan, Annual Cost of Therapy ($), 2013–2020
Figure 28: Major Depressive Disorder Market, Japan, Market Size ($m), 2013–2020
Figure 29: Major Depressive Disorder Market, Global, Deals by Value, Year and Stage of Development, 2006–2013
Figure 30: Major Depressive Disorder Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006–2013
Figure 31: Major Depressive Disorder Market, Global, Licensing Deals by Geography, 2006–2013
Figure 32: Major Depressive Disorder Market, Global, Co-development Deals by Geography, 2006–2013
Figure 33: GBI Research Market Forecasting Model (Example)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports